Figure 1.

PTCy with BBG does not reduce clinical GVHD compared to PTCy alone. (a) Schematic representation of the humanised mouse model of GVHD. (a–e) NSG mice were humanised with 20 × 10⁶ human PBMCs (hPBMCs) (n = 3 donors) on Day 0, treated with cyclophosphamide (33 mg/kg) (Day 3 and 4), and BBG (50 mg/kg) (PTCy + BBG) (n = 10 mice) or saline (PTCy) (n = 11 mice) (Days 0–10). Mice were assessed thrice weekly for (b) weight change, (c) clinical score, (d) ear thickness, and (e) survival. (b–d) Data are presented as mean ± SEM. (e) Data are presented as percent survival, χ² test for mortality.